Is Egrifta (Tesamorelin) Legal in California?

Federal Legal Framework for Tesamorelin

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). The FDA approved branded Egrifta on November 10, 2010, under NDA 022505, specifically for the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. [1] The agency later approved an updated formulation, Egrifta SV (2 mg/vial), which replaced the original 1 mg product. [2]

Because tesamorelin is an FDA-approved drug, federal law treats it as a prescription medicine subject to the Federal Food, Drug, and Cosmetic Act. [3] Physicians in every U.S. State, including California, may prescribe it for its approved indication. Off-label prescribing is also legally permissible under long-standing medical practice doctrine, though the prescriber bears clinical responsibility for that decision.

FDA Approval and the NDA Record

The FDA's Center for Drug Evaluation and Research (CDER) reviewed tesamorelin through two key Phase 3 trials. The IGLOO trials (IGLOO-1 and IGLOO-2, combined N=816) demonstrated that tesamorelin 2 mg/day produced a statistically significant reduction in visceral adipose tissue (VAT) compared with placebo at 26 weeks, with a mean VAT reduction of approximately 18% vs. 2% for placebo (P<0.001). [4] That efficacy data formed the core of the NDA 022505 submission.

Controlled Substance Status

Tesamorelin is not listed in any DEA schedule under the Controlled Substances Act. [5] No DEA registration is required to prescribe or dispense it, which distinguishes it from peptides such as BPC-157 or select secretagogues that remain in regulatory gray areas.

California State Law and Pharmacy Regulations

California does not maintain a separate state-level "approved drug" list that overrides federal FDA approval. A federally approved prescription drug is, by default, prescribable in California once a licensed California prescriber issues a valid prescription. [6]

The California State Board of Pharmacy governs dispensing. Under Title 16 of the California Code of Regulations, any pharmacy dispensing Egrifta must hold an active California pharmacy license, and the dispensing pharmacist must verify the prescription meets standard requirements: patient name, prescriber DEA number (if applicable), date, drug name, strength, quantity, and directions. [7]

Telehealth Prescribing in California

California Business and Professions Code Section 2290.5 permits telehealth prescribing when the prescriber meets the standard of care, including performing or reviewing a sufficient patient evaluation before issuing a prescription. [8] A tesamorelin prescription issued via a compliant California telehealth visit carries the same legal weight as one issued in person.

The Medical Board of California has not issued guidance specifically restricting tesamorelin prescribing. General prescribing obligations apply: the prescriber must establish a valid patient-physician relationship, document clinical indication, and maintain records consistent with CCR Title 16 and Business and Professions Code Section 2266. [9]

Dispensing From Out-of-State Pharmacies

California residents may receive tesamorelin shipped from pharmacies licensed in other states, provided those pharmacies also hold a California Nonresident Pharmacy Permit issued by the California State Board of Pharmacy. [10] Without that permit, the out-of-state pharmacy is operating illegally in California, even if the drug itself is federally approved.

Compounded Tesamorelin: 503A and 503B Rules

Compounding is the area where legal complexity rises sharply. Because branded Egrifta SV is commercially available, federal law creates significant barriers to compounding a copy of the same molecule.

The Section 503A Framework

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a state-licensed compounding pharmacy may prepare individualized preparations for identified patients when specific conditions are met. [11] One of those conditions is that the compounded drug cannot be "essentially a copy" of a commercially available FDA-approved drug, except in cases where the patient has a specific documented clinical difference requiring an alternative formulation.

The FDA's position, articulated in multiple guidance documents, is that compounders wishing to use a bulk drug substance (the active pharmaceutical ingredient in raw form) must either use a substance on the FDA's 503A Bulks List or demonstrate that the substance fits a narrow exemption for clinical necessity. [12] Tesamorelin is not currently on the FDA's published 503A Bulks List. [13]

The Section 503B Outsourcing Facility Framework

Section 503B covers FDA-registered outsourcing facilities that compound without patient-specific prescriptions for distribution to healthcare facilities. [14] The 503B pathway also requires use of bulk drug substances from the 503B Bulks List or substances meeting defined criteria. Like the 503A list, the current 503B Bulks List does not include tesamorelin. [15]

The FDA's January 2017 guidance on "Compounded Drug Products That Are Essentially Copies of Approved Drug Products" states: "A compounded drug product that is essentially a copy of a commercially available drug product may not be compounded under section 503A or 503B." [16] That language applies directly to tesamorelin compounding when Egrifta SV is on the market.

What This Means Practically

A California-licensed 503A pharmacy dispensing compounded tesamorelin to a patient who could use branded Egrifta SV is operating in a legally precarious position under federal law. The FDA has enforcement discretion and does not pursue every violation, but the risk falls on the pharmacy, not the patient. Patients who receive compounded tesamorelin are not committing a crime; the regulatory exposure sits with the compounder.

The framework below summarizes how the federal and California state rules interact for each sourcing scenario:

| Source | Federal Status | California Status | Patient Risk | |--------|---------------|-------------------|--------------| | Branded Egrifta SV via licensed CA pharmacy | Fully legal | Fully legal | None | | Branded Egrifta SV via out-of-state pharmacy with CA permit | Fully legal | Legal | None | | Compounded tesamorelin via 503A CA pharmacy (copy scenario) | Legally uncertain | Follows federal | Minimal | | Compounded tesamorelin via non-registered compounder | Illegal under FDCA | Illegal | Significant | | Raw tesamorelin API purchased online without prescription | Illegal | Illegal | Significant |

How to Get Egrifta (Tesamorelin) in California

Getting tesamorelin legally in California requires three elements: a qualifying clinical indication, a prescription from a licensed California prescriber, and dispensing from a properly licensed pharmacy.

Step 1: Establish a Clinical Indication

The FDA-approved indication is excess abdominal fat (lipodystrophy) in HIV-infected adults. [1] A prescriber may also choose to prescribe tesamorelin off-label, for example in non-HIV patients with documented growth hormone deficiency or metabolic dysfunction, but that decision must be clinically justified and documented. The Endocrine Society's 2019 Clinical Practice Guideline on Growth Hormone Deficiency states that adult GHD diagnosis should be confirmed biochemically before initiating any growth hormone axis therapy. [17]

Step 2: Find a California-Licensed Prescriber

Any MD, DO, NP, or PA licensed in California with prescriptive authority may prescribe tesamorelin. Endocrinologists, infectious disease specialists managing HIV patients, and licensed telehealth platforms operating under California law are all appropriate channels. The prescriber must perform an adequate evaluation, review labs (including IGF-1, fasting glucose, and HbA1c, given tesamorelin's known effects on glucose metabolism [4]), and document clinical rationale.

Step 3: Use a Licensed Pharmacy

Branded Egrifta SV is available through specialty pharmacies. Because tesamorelin is a self-injectable biologic requiring cold-chain handling, most patients obtain it through specialty pharmacy networks. Coverage varies: Medicare Part D and commercial insurers may cover it for the approved HIV lipodystrophy indication with prior authorization. California Medi-Cal coverage requires documentation of HIV diagnosis and lipodystrophy. [18]

Clinical Profile: What Tesamorelin Does

Understanding the mechanism helps contextualize why prescribers consider it and why regulators treat it differently from simple lifestyle medications.

Mechanism of Action

Tesamorelin binds pituitary GHRH receptors and stimulates pulsatile growth hormone (GH) secretion. [19] The resulting rise in GH and downstream IGF-1 promotes lipolysis in visceral adipose tissue. Because it acts on the pituitary rather than directly replacing GH, the physiological pulsatile pattern of GH release is partially preserved, which may reduce side-effect risk compared with exogenous recombinant human GH. [20]

Efficacy Data

The IGLOO trials showed that after 26 weeks of tesamorelin 2 mg/day, 18.1% of treated patients achieved a 20% or greater reduction in VAT by CT scan, compared with 4.2% in the placebo group (P<0.001). [4] A 52-week extension of the IGLOO program published in Clinical Infectious Diseases (N=403) showed that patients who continued treatment maintained VAT reductions, while those switched to placebo regained visceral fat at a rate approximating 8% over the subsequent 26 weeks. [21]

In a separate study published in JAMA Internal Medicine, tesamorelin also reduced liver fat content in HIV-infected patients, with a mean reduction in hepatic fat fraction of 37% vs. 4% in placebo after 12 months. [22]

Safety Considerations

Tesamorelin may raise fasting glucose and insulin levels. In the IGLOO trials, new-onset diabetes occurred in 4.7% of the tesamorelin group vs. 2.1% in placebo. [4] The FDA label carries a warning against use in patients with active malignancy, as GH axis stimulation may theoretically promote tumor growth. [2] Fluid retention, peripheral edema, and arthralgias occur in a minority of patients. Routine monitoring of IGF-1 levels every 6 months is recommended by clinical practice guidance. [17]

Why Some Providers Offer Compounded Tesamorelin Despite the Risks

Several telehealth and men's health platforms market compounded tesamorelin, often framed as a "growth hormone secretagogue" for body composition or anti-aging purposes. The legal tension is real: branded Egrifta SV can cost over $4,000 per month before insurance, and compounded versions are substantially cheaper.

The FDA has sent warning letters to compounding pharmacies producing copies of approved peptides. In 2023 and 2024, multiple warning letters addressed compounders of semaglutide, and the agency's enforcement posture on peptide compounding has been consistent: when a branded product is commercially available, bulk compounding without meeting 503A or 503B exemptions violates federal law. [23]

California's own enforcement is handled by the California State Board of Pharmacy, which may investigate complaints about unlicensed compounders or pharmacies dispensing without proper permits. [7] The Board has authority to revoke pharmacy licenses and refer criminal cases to the California Attorney General.

Comparing Tesamorelin to Other GHRH/Secretagogue Peptides

Tesamorelin's FDA approval gives it a legal advantage over other peptides frequently mentioned in the same clinical conversation.

Sermorelin

Sermorelin was FDA-approved (NDA 020607) but was voluntarily withdrawn from the market in 2008 when the manufacturer ceased production. It is not currently on the FDA Bulks List for 503A compounding, though it has historically been compounded widely. FDA has not finalized its status on the active review list. [24]

CJC-1295 and Ipamorelin

Neither CJC-1295 nor ipamorelin has FDA approval or an IND exemption for clinical use. The FDA placed both on the 503A Bulks List Category 2 (substances that may not be used) in its 2023 proposed rulemaking. [13] Compounding these peptides for clinical use in California is not legally defensible under current federal guidance.

GHRP-6 and Hexarelin

These growth hormone-releasing peptides similarly lack FDA approval and are not on the 503A Bulks List. They are classified as research chemicals. Prescribing or dispensing them for clinical use in California would violate both federal and state law. [3]

Tesamorelin stands apart from this group because it has an active NDA, a commercially available product, and a defined legal prescribing pathway. That distinction matters enormously for both patient safety and legal protection.

Practical Compliance Checklist for California Prescribers

Prescribers in California who want to offer tesamorelin to appropriate patients can do so within clear legal boundaries:

• Confirm the patient meets the approved indication (HIV-associated lipodystrophy) or document clinical rationale for off-label use.
• Order baseline labs: IGF-1, fasting glucose, HbA1c, and a full metabolic panel. [17]
• Prescribe branded Egrifta SV through a licensed specialty pharmacy that holds a California pharmacy permit.
• If considering compounding for cost reasons, consult with the compounding pharmacy's regulatory team about 503A exemptions and document the medical necessity clearly.
• Re-check IGF-1 at 3 months and every 6 months thereafter; adjust dose or discontinue if IGF-1 rises above the age-normalized upper limit of normal.
• Do not prescribe raw tesamorelin API from online vendors. That route is illegal regardless of the state. [3]

Telehealth prescribers must also comply with California Business and Professions Code Section 2290.5, ensuring a sufficient evaluation occurred before the prescription was issued. [8] Ordering a peptide prescription after a 5-minute questionnaire without labs does not meet that standard.